Aarti Drugs Limited — Updates, 18-07-2025: Press Release

Aarti Drugs delivered strong Q1 FY26 financial results: Revenue grew 6% to Rs 590.8 Cr, EBITDA rose 12% to Rs 74.4 Cr, and PAT surged 62% to Rs 54.0 Cr, driven by improved API demand. The company began trial production at its new Sayakha facility for backward integration, aiming to boost margins. Its Salicylic Acid plant at Tarapur is ramping up, targeting 800-1600 tonnes/month capacity by FY26 end. New US tariffs on Chinese pharma imports position Aarti Drugs favorably, supported by recent regulatory approvals and capacity expansions for export markets.